WEN-JEN HWU to Drug Evaluation, Preclinical
This is a "connection" page, showing publications WEN-JEN HWU has written about Drug Evaluation, Preclinical.
Connection Strength
0.035
-
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4).
Score: 0.035